Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 770
Filtrar
1.
Nat Commun ; 15(1): 8849, 2024 Oct 14.
Artigo em Inglês | MEDLINE | ID: mdl-39397005

RESUMO

Hepatitis E virus (HEV) infection, one of the most common forms of hepatitis worldwide, is often associated with extrahepatic, particularly renal, manifestations. However, the underlying mechanisms are incompletely understood. Here, we report the development of a de novo immune complex-mediated glomerulonephritis (GN) in a kidney transplant recipient with chronic hepatitis E. Applying immunostaining, electron microscopy, and mass spectrometry after laser-capture microdissection, we show that GN develops in parallel with increasing glomerular deposition of a non-infectious, genome-free and non-glycosylated HEV open reading frame 2 (ORF2) capsid protein. No productive HEV infection of kidney cells is detected. Patients with acute hepatitis E display similar but less pronounced deposits. Our results establish a link between the production of HEV ORF2 protein and the development of hepatitis E-associated GN in the immunocompromised state. The formation of glomerular IgG-HEV ORF2 immune complexes discovered here provides a potential mechanistic explanation of how the hepatotropic HEV can cause variable renal manifestations. These findings directly provide a tool for etiology-based diagnosis of hepatitis E-associated GN as a distinct entity and suggest therapeutic implications.


Assuntos
Complexo Antígeno-Anticorpo , Glomerulonefrite , Vírus da Hepatite E , Hepatite E , Proteínas Virais , Humanos , Hepatite E/imunologia , Hepatite E/virologia , Hepatite E/patologia , Glomerulonefrite/imunologia , Glomerulonefrite/virologia , Glomerulonefrite/patologia , Vírus da Hepatite E/imunologia , Complexo Antígeno-Anticorpo/imunologia , Proteínas Virais/imunologia , Proteínas Virais/metabolismo , Masculino , Transplante de Rim/efeitos adversos , Pessoa de Meia-Idade , Imunoglobulina G/imunologia , Feminino , Hospedeiro Imunocomprometido , Adulto
2.
BMC Infect Dis ; 24(1): 965, 2024 Sep 12.
Artigo em Inglês | MEDLINE | ID: mdl-39266958

RESUMO

Hepatitis E virus (HEV) is an important emerging pathogen producing significant morbidity in immunosuppressed patients. HEV has been detrimental to solid organ transplant (SOT) patients, cancer patients, and HIV-positive patients, where chronic HEV infections occur. Blood-borne transfusions and multiple cases of chronic HEV infection in transplant patients have been reported in the past few decades, necessitating research on HEV pathogenesis using immunosuppressed animal models. Numerous animal species with unique naturally occurring HEV strains have been found, several of which have the potential to spread to humans and to serve as pathogenesis models. Host immunosuppression leads to viral persistence and chronic HEV infection allows for genetic adaptation to the human host creating new strains with worse disease outcomes. Procedures necessary for SOT often entail blood transfusions placing immunosuppressive patients into a "high risk group" for HEV infection. This scenario requires an appropriate immunosuppressive animal model to understand disease patterns in these patients. Hence, this article reviews the recent advances in the immunosuppressed animal models for chronic HEV infection with emphasis on pathogenesis, immune correlates, and the liver pathology associated with the chronic HEV infections.


Assuntos
Modelos Animais de Doenças , Vírus da Hepatite E , Hepatite E , Hospedeiro Imunocomprometido , Hepatite E/imunologia , Hepatite E/virologia , Animais , Vírus da Hepatite E/imunologia , Vírus da Hepatite E/genética , Humanos
3.
Viruses ; 16(9)2024 Aug 29.
Artigo em Inglês | MEDLINE | ID: mdl-39339854

RESUMO

Hepatitis E virus (HEV) poses a significant global health threat, with an estimated 20 million infections occurring annually. Despite being a self-limiting illness, in most cases, HEV infection can lead to severe outcomes, particularly in pregnant women and individuals with pre-existing liver disease. In the absence of specific antiviral treatments, the exploration of RNAi interference (RNAi) as a targeted strategy provides valuable insights for urgently needed therapeutic interventions against Hepatitis E. We designed small interfering RNAs (siRNAs) against HEV, which target the helicase domain and the open reading frame 3 (ORF3). These target regions will reduce the risk of viral escape through mutations, as they belong to the most conserved regions in the HEV genome. The siRNAs targeting the ORF3 efficiently inhibited viral replication in A549 cells after HEV infection. Importantly, the siRNA was also highly effective at inhibiting HEV in the persistently infected A549 cell line, which provides a suitable model for chronic infection in patients. Furthermore, we showed that a 5' triphosphate modification on the siRNA sense strand activates the RIG-I receptor, a cytoplasmic pattern recognition receptor that recognizes viral RNA. Upon activation, RIG-I triggers a signaling cascade, effectively suppressing HEV replication. This dual-action strategy, combining the activation of the adaptive immune response and the inherent RNAi pathway, inhibits HEV replication successfully and may lead to the development of new therapies.


Assuntos
Proteína DEAD-box 58 , Vírus da Hepatite E , Interferência de RNA , RNA Interferente Pequeno , Replicação Viral , Humanos , Vírus da Hepatite E/fisiologia , Vírus da Hepatite E/genética , Proteína DEAD-box 58/metabolismo , Proteína DEAD-box 58/genética , RNA Interferente Pequeno/genética , Células A549 , Receptores Imunológicos , Hepatite E/virologia , Hepatite E/imunologia , RNA Viral/genética , RNA Viral/metabolismo , Proteínas Virais/genética , Proteínas Virais/metabolismo , Antivirais/farmacologia , Transdução de Sinais
4.
Viruses ; 16(9)2024 Aug 31.
Artigo em Inglês | MEDLINE | ID: mdl-39339876

RESUMO

The zoonotic transmission of hepatitis E virus (HEV) genotypes 3 (HEV-3) and 4 (HEV-4), and rabbit HEV (HEV-3ra) has been documented. Vaccination against HEV infection depends on the capsid (open reading frame 2, ORF2) protein, which is highly immunogenic and elicits effective virus-neutralizing antibodies. Escherichia coli (E. coli) is utilized as an effective system for producing HEV-like particles (VLPs). However, research on the production of ORF2 proteins from these HEV genotypes in E. coli to form VLPs has been modest. In this study, we constructed 21 recombinant plasmids expressing various N-terminally and C-terminally truncated HEV ORF2 proteins for HEV-3, HEV-3ra, and HEV-4 in E. coli. We successfully obtained nine HEV-3, two HEV-3ra, and ten HEV-4 ORF2 proteins, which were primarily localized in inclusion bodies. These proteins were solubilized in 4 M urea, filtered, and subjected to gel filtration. Results revealed that six HEV-3, one HEV-3ra, and two HEV-4 truncated proteins could assemble into VLPs. The purified VLPs displayed molecular weights ranging from 27.1 to 63.4 kDa and demonstrated high purity (74.7-95.3%), as assessed by bioanalyzer, with yields of 13.9-89.6 mg per 100 mL of TB medium. Immunoelectron microscopy confirmed the origin of these VLPs from HEV ORF2. Antigenicity testing indicated that these VLPs possess characteristic HEV antigenicity. Evaluation of immunogenicity in Balb/cAJcl mice revealed robust anti-HEV IgG responses, highlighting the potential of these VLPs as immunogens. These findings suggest that the generated HEV VLPs of different genotypes could serve as valuable tools for HEV research and vaccine development.


Assuntos
Proteínas do Capsídeo , Escherichia coli , Genótipo , Vírus da Hepatite E , Hepatite E , Vacinas de Partículas Semelhantes a Vírus , Vírus da Hepatite E/genética , Vírus da Hepatite E/imunologia , Animais , Coelhos , Escherichia coli/genética , Escherichia coli/metabolismo , Proteínas do Capsídeo/genética , Proteínas do Capsídeo/imunologia , Hepatite E/imunologia , Hepatite E/virologia , Camundongos , Vacinas de Partículas Semelhantes a Vírus/imunologia , Vacinas de Partículas Semelhantes a Vírus/genética , Camundongos Endogâmicos BALB C , Vacinas contra Hepatite Viral/imunologia , Vacinas contra Hepatite Viral/genética , Feminino , Anticorpos Anti-Hepatite/sangue , Anticorpos Anti-Hepatite/imunologia , Anticorpos Neutralizantes/imunologia , Anticorpos Neutralizantes/sangue , Humanos , Anticorpos Antivirais/imunologia , Anticorpos Antivirais/sangue , Proteínas Virais
5.
Virol J ; 21(1): 194, 2024 Aug 23.
Artigo em Inglês | MEDLINE | ID: mdl-39180020

RESUMO

The hepatitis E virus (HEV) is a major cause of acute viral hepatitis worldwide. HEV is classified into eight genotypes, labeled HEV-1 through HEV-8. Genotypes 1 and 2 exclusively infect humans, while genotypes 3, 4, and 7 can infect both humans and animals. In contrast, genotypes 5, 6, and 8 are restricted to infecting animals. While most individuals with a strong immune system experience a self-limiting infection, those who are immunosuppressed may develop chronic hepatitis. Pregnant women are particularly vulnerable to severe illness and mortality due to HEV infection. In addition to liver-related complications, HEV can also cause extrahepatic manifestations, including neurological disorders. The immune response is vital in determining the outcome of HEV infection. Deficiencies in T cells, NK cells, and antibody responses are linked to poor prognosis. Interestingly, HEV itself contains microRNAs that regulate its replication and modify the host's antiviral response. Diagnosis of HEV infection involves the detection of HEV RNA and anti-HEV IgM/IgG antibodies. Supportive care is the mainstay of treatment for acute infection, while chronic HEV infection may be cleared with the use of ribavirin and pegylated interferon. Prevention remains the best approach against HEV, focusing on sanitation infrastructure improvements and vaccination, with one vaccine already licensed in China. This comprehensive review provides insights into the spread, genotypes, prevalence, and clinical effects of HEV. Furthermore, it emphasizes the need for further research and attention to HEV, particularly in cases of acute hepatitis, especially among solid-organ transplant recipients.


Assuntos
Genótipo , Vírus da Hepatite E , Hepatite E , Hepatite E/tratamento farmacológico , Hepatite E/virologia , Hepatite E/epidemiologia , Hepatite E/imunologia , Vírus da Hepatite E/genética , Vírus da Hepatite E/imunologia , Humanos , Animais , Antivirais/uso terapêutico
6.
Front Immunol ; 15: 1445944, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39131153

RESUMO

Background: The hepatitis E virus (HEV) can cause acute viral hepatitis with or without neurological manifestations, and occasionally progresses to chronic infection in immunocompromised individuals. The management of chronic HEV infection in cancer patients may be challenging due to the complex immunological constellation. Furthermore, the diagnostic workflow and the impact on quality of life of neurological HEV manifestations in immunocompromised patients have not been sufficiently delineated previously. Case description: A 61-year-old male with systemically treated chronic lymphocytic leukemia (CLL) experienced a slowly progressive atrophy of the spinal cord due to a chronic HEV infection. Despite continuous antiviral treatment with ribavirin, the patient's neurological condition continued to deteriorate, particularly following subsequent attempts to treat CLL. Treatment with obinutuzumab resulted in acute bowel and urinary retention and a further deterioration of motor skills, prompting the discontinuation of obinutuzumab. The patient's neurological status improved after the administration of intravenous immunoglobulins. Conclusion: This case study provides a comprehensive long-term follow-up of a cancer patient with chronic HEV infection and associated CNS involvement, which resulted in progressive neurological disability over several years. The challenges faced in diagnosing new neurological symptoms in patients undergoing immunosuppressive cancer treatment underscore the need for an interdisciplinary diagnostic approach that includes HEV testing. We propose a diagnostic pathway for future validation in immunocompromised cohorts presenting with neurological symptoms, emphasizing its potential to enhance clinical outcomes.


Assuntos
Atrofia , Hepatite E , Leucemia Linfocítica Crônica de Células B , Humanos , Masculino , Pessoa de Meia-Idade , Leucemia Linfocítica Crônica de Células B/complicações , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Hepatite E/tratamento farmacológico , Hepatite E/complicações , Hepatite E/imunologia , Medula Espinal/patologia , Hospedeiro Imunocomprometido , Vírus da Hepatite E/imunologia , Antivirais/uso terapêutico , Doença Crônica , Anticorpos Monoclonais Humanizados
7.
Sci Rep ; 14(1): 19244, 2024 08 20.
Artigo em Inglês | MEDLINE | ID: mdl-39164378

RESUMO

Guillain-Barré syndrome and neuralgic amyotrophy have been associated with hepatitis E virus (HEV) genotype 3 infections, while myasthenia gravis (MG) has been associated with HEV genotype 4 infections. However, whether chronic inflammatory demyelinating polyneuropathy (CIDP) is associated with HEV infections has not been conclusively clarified yet. 102 CIDP patients, 102 age- and sex-matched blood donors, 61 peripheral neuropathy patients (non-CIDP patients), and 26 MG patients were tested for HEV and anti-HEV IgM and IgG. Sixty-five of the 102 (64%) CIDP patients tested positive for anti-HEV IgG and one (1%) for anti-HEV IgM. No other patient tested positive for ati-HEV IgM. In the subgroup of CIDP patients with initial diagnosis (without previous IVIG treatment), 30/54 (56%) tested positive for anti-HEV IgG. Anti-HEV rates were significantly lower in blood donors (28%), non-CIDP peripheral neuropathy patients (20%), and MG patients (12%). No subject tested positive for HEV viremia. CSF tested negative for in 61 CIDP patients (54 patients with primary diagnosis). The development of CIDP but not non-CIDP polyneuropathy may be triggered by HEV exposure in an HEV genotype 3 endemic region. The increased anti-HEV seroprevalence in CIDP patients is not a consequence of IVIG therapy.


Assuntos
Vírus da Hepatite E , Hepatite E , Imunoglobulina G , Imunoglobulina M , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica , Humanos , Masculino , Feminino , Hepatite E/complicações , Hepatite E/sangue , Hepatite E/imunologia , Pessoa de Meia-Idade , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/sangue , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/diagnóstico , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/imunologia , Adulto , Idoso , Vírus da Hepatite E/imunologia , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Anticorpos Anti-Hepatite/sangue
8.
J Viral Hepat ; 31(11): 729-738, 2024 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-39136210

RESUMO

Hepatitis E virus (HEV) is a foodborne zoonotic pathogen that is supposed to be one of the most common causes of acute viral hepatitis. However, HEV infection has been recently associated with a wide spectrum of extrahepatic manifestations, particularly neurological disorders. Previous studies have shown that HEV is able to cross the blood-brain barrier (BBB) and induce inflammatory response of the central nervous system. However, the pathogenesis of HEV-induced neuroinflammation and tissue injury of the central nervous system have yet to be fully elucidated. In this study, activation of NLRP3 inflammasome following HEV infection were investigated. In a gerbil model infected by HEV, brain histopathological changes including gliosis, neuronophagia and neuron injury were observed and expression of NLRP3, caspase-1, IL-1ß and IL-18 were elevated. Brain microvascular endothelial cells (BMECs) are key components of the BBB that protects the brain from various challenges. Following HEV infection, virus-like particles range from 30 to 40 nm in diameter were observed in human BMECs (hBMECs). Enhanced expression levels of NLRP3 and subsequent ASC, caspase-1, IL-1ß and IL-18 were detected in infected cells. Treatment with MCC950 alleviated HEV infection induced activation of NLRP3 inflammasome, mitochondrial damage and VE-cadherin degradation. The findings provide new insights into HEV-associated neuroinflammation. Moreover, targeting NLRP3 inflammasome signalling is a promising therapeutic in HEV-induced neurological disorder.


Assuntos
Encéfalo , Modelos Animais de Doenças , Células Endoteliais , Gerbillinae , Vírus da Hepatite E , Hepatite E , Inflamassomos , Proteína 3 que Contém Domínio de Pirina da Família NLR , Doenças Neuroinflamatórias , Animais , Proteína 3 que Contém Domínio de Pirina da Família NLR/metabolismo , Inflamassomos/metabolismo , Inflamassomos/imunologia , Vírus da Hepatite E/imunologia , Vírus da Hepatite E/fisiologia , Doenças Neuroinflamatórias/virologia , Doenças Neuroinflamatórias/patologia , Doenças Neuroinflamatórias/imunologia , Hepatite E/virologia , Hepatite E/patologia , Hepatite E/complicações , Hepatite E/imunologia , Células Endoteliais/virologia , Encéfalo/patologia , Encéfalo/virologia , Humanos , Barreira Hematoencefálica/virologia , Sulfonas/farmacologia , Indenos , Furanos/farmacologia , Sulfonamidas/farmacologia , Compostos Heterocíclicos de 4 ou mais Anéis/farmacologia , Masculino , Interleucina-1beta/metabolismo , Interleucina-18/metabolismo
9.
Nat Rev Gastroenterol Hepatol ; 21(10): 710-725, 2024 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-39039260

RESUMO

Hepatitis E virus (HEV) infections are a major cause of acute viral hepatitis in humans worldwide. In immunocompetent individuals, the majority of HEV infections remain asymptomatic and lead to spontaneous clearance of the virus, and only a minority of individuals with infection (5-16%) experience symptoms of acute viral hepatitis. However, HEV infections can cause up to 30% mortality in pregnant women, become chronic in immunocompromised patients and cause extrahepatic manifestations. A growing body of evidence suggests that the host immune response to infection with different HEV genotypes is a critical determinant of distinct HEV infection outcomes. In this Review, we summarize key components of the innate and adaptive immune responses to HEV, including the underlying immunological mechanisms of HEV associated with acute and chronic liver failure and interactions between T cell and B cell responses. In addition, we discuss the current status of vaccines against HEV and raise outstanding questions regarding the immune responses induced by HEV and treatment of the disease, highlighting areas for future investigation.


Assuntos
Imunidade Adaptativa , Vírus da Hepatite E , Hepatite E , Imunidade Inata , Humanos , Hepatite E/imunologia , Vírus da Hepatite E/imunologia , Imunidade Inata/imunologia , Imunidade Adaptativa/imunologia , Vacinas contra Hepatite Viral/imunologia
10.
Viruses ; 16(7)2024 Jul 08.
Artigo em Inglês | MEDLINE | ID: mdl-39066255

RESUMO

A wide range of virus-like particles (VLPs) is extensively employed as carriers to display various antigens for vaccine development to fight against different infections. The plant-produced truncated variant of the hepatitis E virus (HEV) coat protein is capable of forming VLPs. In this study, we demonstrated that recombinant fusion proteins comprising truncated HEV coat protein with green fluorescent protein (GFP) or four tandem copies of the extracellular domain of matrix protein 2 (M2e) of influenza A virus inserted at the Tyr485 position could be efficiently expressed in Nicotiana benthamiana plants using self-replicating vector based on the potato virus X genome. The plant-produced fusion proteins in vivo formed VLPs displaying GFP and 4M2e. Therefore, HEV coat protein can be used as a VLP carrier platform for the presentation of relatively large antigens comprising dozens to hundreds of amino acids. Furthermore, plant-produced HEV particles could be useful research tools for the development of recombinant vaccines against influenza.


Assuntos
Apresentação de Antígeno , Proteínas do Capsídeo , Vírus da Hepatite E , Nicotiana , Proteínas Recombinantes de Fusão , Proteínas da Matriz Viral , Vírus da Hepatite E/imunologia , Vírus da Hepatite E/genética , Nicotiana/virologia , Nicotiana/genética , Proteínas do Capsídeo/genética , Proteínas do Capsídeo/imunologia , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/imunologia , Proteínas da Matriz Viral/genética , Proteínas da Matriz Viral/imunologia , Proteínas de Fluorescência Verde/genética , Proteínas de Fluorescência Verde/metabolismo , Vacinas de Partículas Semelhantes a Vírus/imunologia , Vacinas de Partículas Semelhantes a Vírus/genética , Plantas Geneticamente Modificadas , Vírus da Influenza A/imunologia , Vírus da Influenza A/genética , Hepatite E/imunologia , Hepatite E/prevenção & controle , Hepatite E/virologia , Proteínas Viroporinas
11.
J Virol ; 98(7): e0084624, 2024 Jul 23.
Artigo em Inglês | MEDLINE | ID: mdl-38899900

RESUMO

Chronic hepatitis E mostly occurs in organ transplant recipients and can lead to rapid liver fibrosis and cirrhosis. Previous studies found that the development of chronic hepatitis E virus (HEV) infection is linked to the type of immunosuppressant used. Animal models are crucial for the study of pathogenesis of chronic hepatitis E. We previously established a stable chronic HEV infection rabbit model using cyclosporine A (CsA), a calcineurin inhibitor (CNI)-based immunosuppressant. However, the immunosuppression strategy and timing may be optimized, and how different types of immunosuppressants affect the establishment of chronic HEV infection in this model is still unknown. Here, we showed that chronic HEV infection can be established in 100% of rabbits when CsA treatment was started at HEV challenge or even 4 weeks after. Tacrolimus or prednisolone treatment alone also contributed to chronic HEV infection, resulting in 100% and 77.8% chronicity rates, respectively, while mycophenolate mofetil (MMF) only led to a 28.6% chronicity rate. Chronic HEV infection was accompanied with a persistent activation of innate immune response evidenced by transcriptome analysis. The suppressed adaptive immune response evidenced by low expression of genes related to cytotoxicity (like perforin and FasL) and low anti-HEV seroconversion rates may play important roles in causing chronic HEV infection. By analyzing HEV antigen concentrations with different infection outcomes, we also found that HEV antigen levels could indicate chronic HEV infection development. This study optimized the immunosuppression strategies for establishing chronic HEV infection in rabbits and highlighted the potential association between the development of chronic HEV infection and immunosuppressants.IMPORTANCEOrgan transplant recipients are at high risk of chronic hepatitis E and generally receive a CNI-based immunosuppression regimen containing CNI (tacrolimus or CsA), MMF, and/or corticosteroids. Previously, we established stable chronic HEV infection in a rabbit model by using CsA before HEV challenge. In this study, we further optimized the immunosuppression strategies for establishing chronic HEV infection in rabbits. Chronic HEV infection can also be established when CsA treatment was started at the same time or even 4 weeks after HEV challenge, clearly indicating the risk of progression to chronic infection under these circumstances and the necessity of HEV screening for both the recipient and the donor preoperatively. CsA, tacrolimus, or prednisolone instead of MMF significantly contributed to chronic HEV infection. HEV antigen in acute infection phase indicates the development of chronic infection. Our results have important implications for understanding the potential association between chronic HEV infection and immunosuppressants.


Assuntos
Ciclosporina , Modelos Animais de Doenças , Vírus da Hepatite E , Hepatite E , Terapia de Imunossupressão , Imunossupressores , Tacrolimo , Animais , Coelhos , Hepatite E/imunologia , Hepatite E/virologia , Hepatite E/tratamento farmacológico , Vírus da Hepatite E/imunologia , Imunossupressores/farmacologia , Imunossupressores/uso terapêutico , Ciclosporina/farmacologia , Ciclosporina/uso terapêutico , Tacrolimo/farmacologia , Tacrolimo/uso terapêutico , Prednisolona/uso terapêutico , Prednisolona/farmacologia , Masculino , Imunidade Inata/efeitos dos fármacos , Ácido Micofenólico/farmacologia , Hepatite Crônica/tratamento farmacológico , Hepatite Crônica/imunologia , Hepatite Crônica/virologia , Doença Crônica , Inibidores de Calcineurina/farmacologia , Inibidores de Calcineurina/uso terapêutico
12.
J Immunol ; 213(4): 442-455, 2024 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-38905108

RESUMO

Hepatitis E virus (HEV) is a worldwide zoonotic and public health concern. The study of HEV biology is helpful for designing viral vaccines and drugs. Nanobodies have recently been considered appealing materials for viral biological research. In this study, a Bactrian camel was immunized with capsid proteins from different genotypes (1, 3, 4, and avian) of HEV. Then, a phage library (6.3 × 108 individual clones) was constructed using peripheral blood lymphocytes from the immunized camel, and 12 nanobodies against the truncated capsid protein of genotype 3 HEV (g3-p239) were screened. g3-p239-Nb55 can cross-react with different genotypes of HEV and block Kernow-C1/P6 HEV from infecting HepG2/C3A cells. To our knowledge, the epitope recognized by g3-p239-Nb55 was determined to be a novel conformational epitope located on the surface of viral particles and highly conserved among different mammalian HEV isolates. Next, to increase the affinity and half-life of the nanobody, it was displayed on the surface of ferritin, which can self-assemble into a 24-subunit nanocage, namely, fenobody-55. The affinities of fenobody-55 to g3-p239 were ∼20 times greater than those of g3-p239-Nb55. In addition, the half-life of fenobody-55 was nine times greater than that of g3-p239-Nb55. G3-p239-Nb55 and fenobody-55 can block p239 attachment and Kernow-C1/P6 infection of HepG2/C3A cells. Fenobody-55 can completely neutralize HEV infection in rabbits when it is preincubated with nonenveloped HEV particles. Our study reported a case in which a nanobody neutralized HEV infection by preincubation, identified a (to our knowledge) novel and conserved conformational epitope of HEV, and provided new material for researching HEV biology.


Assuntos
Anticorpos Neutralizantes , Proteínas do Capsídeo , Vírus da Hepatite E , Hepatite E , Anticorpos de Domínio Único , Vírus da Hepatite E/imunologia , Animais , Proteínas do Capsídeo/imunologia , Anticorpos de Domínio Único/imunologia , Humanos , Anticorpos Neutralizantes/imunologia , Hepatite E/imunologia , Camelus/imunologia , Epitopos/imunologia , Células Hep G2 , Reações Cruzadas/imunologia , Genótipo , Especificidade de Anticorpos/imunologia
13.
J Viral Hepat ; 31(8): 446-456, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38727597

RESUMO

Hepatitis E virus (HEV) is a foodborne virus transmitted through the faecal-oral route that causes viral hepatitis in humans worldwide. Ever since its discovery as a zoonotic agent, HEV was isolated from several species with an expanding range of hosts. HEV possesses several features of other RNA viruses but also has certain HEV-specific traits that make its viral-host interactions inimitable. HEV leads to severe morbidity and mortality in immunocompromised people and pregnant women across the world. The situation in underdeveloped countries is even more alarming. Even after creating a menace across the world, we still lack an effective vaccine against HEV. Till date, there is only one licensed vaccine for HEV available only in China. The development of an anti-HEV vaccine that can reduce HEV-induced morbidity and mortality is required. Live attenuated and killed vaccines against HEV are not accessible due to the lack of a tolerant cell culture system, slow viral replication kinetics and varying growth conditions. Thus, the main focus for anti-HEV vaccine development is now on the molecular approaches. In the current study, we have designed a multi-epitope vaccine against HEV through a reverse vaccinology approach. For the first time, we have used viral ORF3, capsid protein and polyprotein altogether for epitope prediction. These are crucial for viral replication and persistence and are major vaccine targets against HEV. The proposed in silico vaccine construct comprises of highly immunogenic and antigenic T-cell and B-cell epitopes of HEV proteins. The construct is capable of inducing an effective and long-lasting host immune response as evident from the simulation results. In addition, the construct is stable, non-allergic and antigenic for the host. Altogether, our findings suggest that the in silico vaccine construct may be useful as a vaccine candidate for preventing HEV infections.


Assuntos
Simulação por Computador , Hepatite E , Vacinas de Subunidades Proteicas , Vacinas contra Hepatite Viral , Humanos , Epitopos/imunologia , Epitopos/genética , Epitopos de Linfócito B/imunologia , Epitopos de Linfócito B/genética , Epitopos de Linfócito T/imunologia , Epitopos de Linfócito T/genética , Hepatite E/prevenção & controle , Hepatite E/imunologia , Vírus da Hepatite E/imunologia , Vírus da Hepatite E/genética , Vacinas de Subunidades Proteicas/imunologia , Desenvolvimento de Vacinas , Vacinas contra Hepatite Viral/imunologia , Proteínas Virais/imunologia , Proteínas Virais/genética
15.
J Med Virol ; 96(5): e29639, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38708824

RESUMO

Hepatitis E virus (HEV) infection in pregnant women is associated with a wide spectrum of adverse consequences for both mother and fetus. The high mortality in this population appears to be associated with hormonal changes and consequent immunological changes. This study conducted an analysis of immune responses in pregnant women infected with HEV manifesting varying severity. Data mining analysis of the GSE79197 was utilized to examine differentially biological functions in pregnant women with HEV infection (P-HEV) versus without HEV infection (P-nHEV), P-HEV progressing to ALF (P-ALF) versus P-HEV, and P-HEV versus non-pregnant women with HEV infection (nP-HEV). We found cellular response to interleukin and immune response-regulating signalings were activated in P-HEV compared with P-nHEV. However, there was a significant decrease of immune responses, such as T cell activation, leukocyte cell-cell adhesion, regulation of lymphocyte activation, and immune response-regulating signaling pathway in P-ALF patient than P-HEV patient. Compared with nP-HEV, MHC protein complex binding function was inhibited in P-HEV. Further microRNA enrichment analysis showed that MAPK and T cell receptor signaling pathways were inhibited in P-HEV compared with nP-HEV. In summary, immune responses were activated during HEV infection while being suppressed when developing ALF during pregnancy, heightening the importance of immune mediation in the pathogenesis of severe outcome in HEV infected pregnant women.


Assuntos
Vírus da Hepatite E , Hepatite E , Complicações Infecciosas na Gravidez , Humanos , Feminino , Gravidez , Hepatite E/imunologia , Hepatite E/virologia , Complicações Infecciosas na Gravidez/virologia , Complicações Infecciosas na Gravidez/imunologia , Vírus da Hepatite E/imunologia , Transdução de Sinais , Falência Hepática Aguda/imunologia , Falência Hepática Aguda/virologia , MicroRNAs/genética , Adulto
16.
Gastroenterology ; 167(4): 750-763.e10, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38582270

RESUMO

BACKGROUND & AIMS: Hepatitis E virus (HEV), primarily genotype 1 (HEV-1), causes approximately 20.1 million infections, 44,000 deaths, and 3000 stillbirths annually. Current evidence indicates that HEV-1 is only transmitted in humans. Here, we evaluated whether Mongolian gerbils can serve as animal models for HEV-1 infection. METHODS: Mongolian gerbils were used for HEV-1 and hepatitis E virus genotype 3 infection experiments. HEV infection parameters, including detection of HEV RNA and HEV antigen, liver function assessment, and histopathology, were evaluated. RESULTS: We adapted a clinical isolate of HEV-1 for Mongolian gerbils by serial passaging in feces of aged male gerbils. The gerbil-adapted strain obtained at passage 3 induced a robust, acute HEV infection, characterized by stable fecal virus shedding, elevated liver enzymes, histopathologic changes in the liver, and seroconversion to anti-HEV. An infectious complementary DNA clone of the adapted virus was generated. HEV-1-infected pregnant gerbils showed a high rate of maternal mortality and vertical transmission. HEV RNA or antigens were detected in the liver, kidney, intestine, placenta, testis, and fetus liver. Liver and placental transcriptomic analyses indicated activation of host immunity. Tacrolimus prolonged HEV-1 infection, whereas ribavirin cleared infection. The protective efficacy of a licensed HEV vaccine was validated using this model. CONCLUSIONS: HEV-1 efficiently infected Mongolian gerbils. This HEV-1 infection model will be valuable for investigating hepatitis E immunopathogenesis and evaluating vaccines and antivirals against HEV.


Assuntos
Modelos Animais de Doenças , Genótipo , Gerbillinae , Vírus da Hepatite E , Hepatite E , Imunocompetência , Fígado , RNA Viral , Animais , Vírus da Hepatite E/genética , Vírus da Hepatite E/patogenicidade , Vírus da Hepatite E/imunologia , Hepatite E/virologia , Hepatite E/imunologia , Hepatite E/transmissão , Masculino , Feminino , RNA Viral/isolamento & purificação , RNA Viral/análise , Fígado/virologia , Fígado/patologia , Fezes/virologia , Gravidez , Transmissão Vertical de Doenças Infecciosas , Antivirais/uso terapêutico , Antivirais/farmacologia , Eliminação de Partículas Virais , Ribavirina/uso terapêutico , Ribavirina/farmacologia , Complicações Infecciosas na Gravidez/virologia , Complicações Infecciosas na Gravidez/imunologia
17.
Am J Trop Med Hyg ; 110(6): 1210-1213, 2024 Jun 05.
Artigo em Inglês | MEDLINE | ID: mdl-38653231

RESUMO

We explored the association between serological status for hepatitis E and neurocysticercosis (NCC) in neurologic patients attending a national neurological referral center in Lima, Perú, between the years 2008 and 2012. Anti-hepatitis E antibodies were evaluated in patients with and without NCC, and a control group of rural general population. Anti-hepatitis E IgG was found in 23.8% of patients with NCC, compared with 14.3% in subjects without NCC from a general rural population (P = 0.023) and 14.4% in subjects with neurological complaints without NCC (P = 0.027). Seropositive patients had a median age of 44 years compared with 30 years in seronegative patients (P <0.001). No significant differences in sex, region of residence, or liver enzyme values were found. Seropositivity to hepatitis E was frequent in this Peruvian population and higher in patients with NCC, suggesting shared common routes of infection.


Assuntos
Vírus da Hepatite E , Hepatite E , Neurocisticercose , Humanos , Neurocisticercose/epidemiologia , Neurocisticercose/imunologia , Neurocisticercose/complicações , Masculino , Adulto , Feminino , Hepatite E/epidemiologia , Hepatite E/imunologia , Vírus da Hepatite E/imunologia , Pessoa de Meia-Idade , Peru/epidemiologia , Adulto Jovem , Prevalência , Imunoglobulina G/sangue , Anticorpos Anti-Hepatite/sangue , Estudos Soroepidemiológicos , Adolescente , Idoso
18.
Curr Drug Saf ; 19(3): 377-381, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38204276

RESUMO

INTRODUCTION: Heparin is derived from swine and has been suggested as a possible source of HEV. To study the potential risk of HEV infection associated with heparin treatment, two groups of individuals were compared. Sera from heparinized (N=93) and non-heparinized individuals (N=111) were tested for markers of acute HEV infection and anti-HEV IgG seroprevalence. METHODS: An acute HEV case was defined by the presence of anti-HEV IgM and/or HEV RNA. From the 93 heparinized individuals, one was positive for IgM and IgG anti-HEV and two were positive for HEV RNA (for both ORF3 and ORF2), and there were a total of two (2.2%) cases of current or recent HEV infection. From the 111 non-heparinized individuals, three were positive for IgM anti-HEV, one was positive for both IgM and IgG anti-HEV, and none was positive for HEV RNA, and there were a total of three (2.7%) cases of current or recent HEV infection. The difference between HEV cases in the heparinized individuals and the non-heparinized individuals was not statistically significant (2.2% vs. 2.7%; p = 0.799). RESULTS: Concerning IgG anti-HEV, it was detected in 32 individuals from the heparinized group and in 18 from the non-heparinized control group. A statistically significant difference was observed in the presence of anti-HEV IgG in heparinized individuals and controls (p = 0.003). CONCLUSION: This study has not found any association between heparin treatment and acute HEV infection, but has shown the use of therapeutic heparin as a risk factor for IgG anti-HEV seropositivity.


Assuntos
Heparina , Vírus da Hepatite E , Hepatite E , Imunoglobulina G , Imunoglobulina M , Heparina/imunologia , Heparina/efeitos adversos , Humanos , Hepatite E/imunologia , Hepatite E/epidemiologia , Vírus da Hepatite E/imunologia , Vírus da Hepatite E/genética , Masculino , Pessoa de Meia-Idade , Feminino , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Adulto , Idoso , Estudos Soroepidemiológicos , Anticorpos Anti-Hepatite/sangue , RNA Viral/sangue , Idoso de 80 Anos ou mais , Adulto Jovem , Anticoagulantes/uso terapêutico , Anticoagulantes/efeitos adversos
19.
Curr Microbiol ; 79(2): 44, 2022 Jan 04.
Artigo em Inglês | MEDLINE | ID: mdl-34982235

RESUMO

Hepatitis E contributes to 3.3 million acute hepatitis cases worldwide with 30% mortality in pregnant women. Pathogenesis of Hepatitis E is complex; thus, the present study was aimed at inflammasomes and associated cytokines in the immunopathogenesis of viral hepatitis E. PBMCs were isolated from 45 HEV IgM/HEV RNA-positive AVH/ALF and 19 healthy individuals and processed for mRNA expressions of NLRs, RLRs, and cytokines. PBMCs were cultured and stimulated with HEV-pORF-2 peptide in vitro for mRNA expression by RT-PCR and cytokines levels in serum/culture supernatant by ELISA. siRNA transfection and post-silencing effect in AVH PBMCs were also assessed by NLRP3 gene expression and IL-1ß and IL-18 levels by ELISA. The results demonstrated high viral load in ALF than AVH cases. mRNA expression of NLRP3 in AVH patients was found to be positively correlated with IL-18 (r = 0.74) and IL-1ß (r = 0.68); P < 0.0001***. Significant levels of serum IL-1ß and IL-18 cytokines were observed in AVH as compared to ALF patients. The levels of IL-1ß in the culture supernatant in mock and stimulated conditions were significantly higher in AVH than in ALF patients. Significant downregulation in NLRP3 gene expression was correlated with the reduced levels of IL-1ß and IL-18 cytokines in NLRP3-siRNA-transfected PBMCs. This study highlighted the significance of upregulated NLRP3 inflammasome leading to increased production of IL-18 and IL-1ß cytokines in sera of AVH patients. Thus, it indicated the role of Th1 response acting through the NLRP3 pathway which might have been helpful in the recovery of AVH patients. These promising results open multiple treatment avenues where specific inhibitors can be designed to modulate the progress of disease and its pathogenicity.


Assuntos
Hepatite E , Inflamassomos , Proteína 3 que Contém Domínio de Pirina da Família NLR/imunologia , Células Cultivadas , Citocinas/imunologia , Feminino , Hepatite E/imunologia , Humanos , Inflamassomos/imunologia , Gravidez , Prognóstico , Linfócitos T/imunologia , Carga Viral
20.
Hepatology ; 75(1): 196-212, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34392558

RESUMO

BACKGROUND AND AIMS: HEV infection is the most common cause of liver inflammation, but the pathogenic mechanisms remain largely unclear. We aim to explore whether HEV infection activates inflammasomes, crosstalk with antiviral interferon response, and the potential of therapeutic targeting. APPROACH AND RESULTS: We measured IL-1ß secretion, the hallmark of inflammasome activation, in serum of HEV-infected patients and rabbits, and in cultured macrophage cell lines and primary monocyte-derived macrophages. We found that genotypes 3 and 4 HEV infection in rabbits elevated IL-1ß production. A profound increase of IL-1ß secretion was further observed in HEV-infected patients (1,733 ± 1,234 pg/mL; n = 70) compared to healthy persons (731 ± 701 pg/mL; n = 70). Given that macrophages are the drivers of inflammatory response, we found that inoculation with infectious HEV particles robustly triggered NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome activation in primary macrophages and macrophage cell lines. We further revealed that the ORF2 capsid protein and the formed integral viral particles are responsible for activating inflammasome response. We also identified NF-κB signaling activation as a key upstream event of HEV-induced NLRP3 inflammasome response. Interestingly, inflammasome activation antagonizes interferon response to facilitate viral replication in macrophages. Pharmacological inhibitors and clinically used steroids can effectively target inflammasome activation. Combining steroids with ribavirin simultaneously inhibits HEV and inflammasome response without cross-interference. CONCLUSIONS: HEV infection strongly activates NLRP3 inflammasome activation in macrophages, which regulates host innate defense and pathogenesis. Therapeutic targeting of NLRP3, in particular when combined with antiviral agents, represents a viable option for treating severe HEV infection.


Assuntos
Vírus da Hepatite E/imunologia , Hepatite E/imunologia , Inflamassomos/metabolismo , Proteína 3 que Contém Domínio de Pirina da Família NLR/metabolismo , Animais , Antivirais/farmacologia , Antivirais/uso terapêutico , Modelos Animais de Doenças , Hepatite E/sangue , Hepatite E/tratamento farmacológico , Hepatite E/virologia , Interações Hospedeiro-Patógeno/imunologia , Humanos , Inflamassomos/antagonistas & inibidores , Inflamassomos/imunologia , Interferons/metabolismo , Interleucina-1beta/sangue , Interleucina-1beta/metabolismo , Macrófagos/efeitos dos fármacos , Macrófagos/imunologia , Macrófagos/metabolismo , NF-kappa B/metabolismo , Proteína 3 que Contém Domínio de Pirina da Família NLR/antagonistas & inibidores , Cultura Primária de Células , Coelhos , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/imunologia , Células THP-1
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA